TREACE MEDICAL CONCEPTS, INC. (TMCI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 25M 50M 75M Q3 '21: 21.6M Q4 '21: 33.4M Q1 '22: 29M Q2 '22: 30M Q3 '22: 33.1M Q4 '22: 49.8M Q1 '23: 42.2M Q2 '23: 42M Q3 '23: 40.8M Q4 '23: 62.2M Q1 '24: 51.1M Q2 '24: 44.5M Q3 '24: 45.1M Q4 '24: 68.7M Q1 '25: 52.6M Q2 '25: 47.4M Q3 '25: 50.2M Q4 '25: 62.5M Q1 '26: 47.2M Q2 '26: 45.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 20M 40M 60M Q3 '21: 17.4M Q4 '21: 28.1M Q1 '22: 23.9M Q2 '22: 24.7M Q3 '22: 27M Q4 '22: 40.7M Q1 '23: 34.2M Q2 '23: 34.3M Q3 '23: 32.8M Q4 '23: 50.7M Q1 '24: 41M Q2 '24: 35.7M Q3 '24: 36.1M Q4 '24: 55.5M Q1 '25: 41.9M Q2 '25: 37.8M Q3 '25: 39.7M Q4 '25: 50.4M Q1 '26: 37.4M Q2 '26: 35.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -5.5M Q4 '21: -5.6M Q1 '22: -8.1M Q2 '22: -11.9M Q3 '22: -11.3M Q4 '22: -3.5M Q1 '23: -13.8M Q2 '23: -13.1M Q3 '23: -17.8M Q4 '23: -6.8M Q1 '24: -19M Q2 '24: -21.4M Q3 '24: -15.1M Q4 '24: -204K Q1 '25: -15.6M Q2 '25: -17M Q3 '25: -15.7M Q4 '25: -5.9M Q1 '26: -17.2M Q2 '26: -15M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -6.4M Q4 '21: -6.6M Q1 '22: -9M Q2 '22: -17.2M Q3 '22: -12.1M Q4 '22: -4.4M Q1 '23: -13.5M Q2 '23: -12.3M Q3 '23: -17.5M Q4 '23: -6.3M Q1 '24: -18.7M Q2 '24: -21.2M Q3 '24: -15.4M Q4 '24: -501K Q1 '25: -15.9M Q2 '25: -17.4M Q3 '25: -16.3M Q4 '25: -9.4M Q1 '26: -18M Q2 '26: -15.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 5M 10M 15M Q3 '21: 4.2M Q4 '21: 5.4M Q1 '22: 5.1M Q2 '22: 5.3M Q3 '22: 6.1M Q4 '22: 9M Q1 '23: 8M Q2 '23: 7.7M Q3 '23: 8M Q4 '23: 11.5M Q1 '24: 10.1M Q2 '24: 8.8M Q3 '24: 9M Q4 '24: 13.2M Q1 '25: 10.7M Q2 '25: 9.6M Q3 '25: 10.5M Q4 '25: 12.1M Q1 '26: 9.8M Q2 '26: 9.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '21: -9.3M Q4 '21: -3.8M Q1 '22: -7.2M Q2 '22: -10.6M Q3 '22: -7.5M Q4 '22: -5.4M Q1 '23: -17.3M Q2 '23: -8.3M Q3 '23: -9.5M Q4 '23: 532K Q1 '24: -7.2M Q2 '24: -13.9M Q3 '24: -11.8M Q4 '24: -4.2M Q1 '25: 4.2M Q2 '25: -3M Q3 '25: -9.1M Q4 '25: -8M Q1 '26: 7.2M Q2 '26: -4.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -10.2M Q4 '21: -4.7M Q1 '22: -8.7M Q2 '22: -15.7M Q3 '22: -13.3M Q4 '22: -7.7M Q1 '23: -18.7M Q2 '23: -12.6M Q3 '23: -13M Q4 '23: -1.7M Q1 '24: -11.1M Q2 '24: -15.6M Q3 '24: -14.7M Q4 '24: -7.3M Q1 '25: 655K Q2 '25: -7.8M Q3 '25: -11.9M Q4 '25: -10.4M Q1 '26: 4.2M Q2 '26: -6.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '21: 49.2M Q3 '21: 52.8M Q1 '22: 54.8M Q2 '22: 55.3M Q3 '22: 55.4M Q1 '23: 58.7M Q2 '23: 61.4M Q3 '23: 61.6M Q1 '24: 61.8M Q2 '24: 62.1M Q3 '24: 62.2M Q1 '25: 62.7M Q2 '25: 63M Q3 '25: 63.5M Q1 '26: 64.6M Q2 '26: 65M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.05 -0.70 -0.35 0.00 0.35 0.70 1.05 Q3 '21: -0.22 Q4 '21: -0.42 Q1 '22: -0.51 Q2 '22: -0.72 Q3 '22: -0.82 Q4 '22: -0.76 Q1 '23: -0.83 Q2 '23: -0.72 Q3 '23: -0.78 Q4 '23: -0.81 Q1 '24: -0.88 Q2 '24: -1.02 Q3 '24: -0.99 Q4 '24: -0.90 Q1 '25: -0.85 Q2 '25: -0.79 Q3 '25: -0.80 Q4 '25: -0.93 Q1 '26: -0.96 Q2 '26: -0.92 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.